{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:05:59Z","timestamp":1793905559826,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head Face Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the present study was to examine the cytostatic effects of cold atmospheric plasma (CAP) on different head and neck squamous carcinoma (HNSCC) cell lines either in isolation or in combination with low dose cisplatin. The effect of CAP treatment was investigated by using three different HNSCC cell lines (chemo-resistant Cal 27, chemo-sensitive FaDu and OSC 19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and method<\/jats:title>\n                    <jats:p>Cell lines were exposed to CAP treatment for 30, 60, 90, 120 and 180\u00a0s (s). Cisplatin was added concurrently (cc) or 24\u00a0h after CAP application (cs). Cell viability, DNA damage and apoptosis was evaluated by dye exclusion, MTT, alkaline microgel electrophoresis assay and Annexin V-Fit-C\/PI respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all cell lines, 120\u00a0s of CAP exposure resulted in a significant reduction of cell viability. DNA damage significantly increased after 60\u00a0s. Combined treatment of cells with CAP and low dose cisplatin showed additive effects. A possible sensitivity to cisplatin could be restored in Cal 27 cells by CAP application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAP shows strong cytostatic effects in HNSCC cell lines that can be increased by concurrent cisplatin treatment, suggesting that CAP may enhance the therapeutic efficacy of low dose cisplatin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13005-022-00322-5","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T11:09:09Z","timestamp":1656500949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells\u2014an in-vitro study"],"prefix":"10.1186","volume":"18","author":[{"given":"Teresa F.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian A.","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Troeltzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Schwenk-Zieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia L.","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Morfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Harr\u00e9us","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Welz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374\u2013403. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.027.","DOI":"10.1016\/j.ejca.2012.12.027"},{"issue":"7","key":"322_CR2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/(SICI)1097-0347(199810)20:7<588::AID-HED2>3.0.CO;2-F","volume":"20","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, et al. Precisely defining high-risk operable head and neck tumors based on rtog #85-03 and #88-24: Targets for postoperative radiochemotherapy? Head Neck. 1999;20(7):588\u201394.","journal-title":"Head Neck"},{"key":"322_CR3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"key":"322_CR4","doi-asserted-by":"publisher","unstructured":"Bauml JM, Vinnakota R, Anna Park YH, et al. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. J Natl Cancer Inst. 2019;111(5):490\u20137. https:\/\/doi.org\/10.1093\/jnci\/djy133.","DOI":"10.1093\/jnci\/djy133"},{"issue":"9","key":"322_CR5","first-page":"2742","volume":"10","author":"H Picon","year":"2020","unstructured":"Picon H, Guddati AK. Mechanisms of resistance in head and neck cancer. Am J Cancer Res. 2020;10(9):2742.","journal-title":"Am J Cancer Res"},{"issue":"15","key":"322_CR6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"1","key":"322_CR7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"A-M Florea","year":"2011","unstructured":"Florea A-M, B\u00fcsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3(1):1351\u201371.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"322_CR8","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/cam4.2139","volume":"8","author":"M Furqan","year":"2019","unstructured":"Furqan M, et al. Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC). Cancer Med. 2019;8(6):2730\u20139.","journal-title":"Cancer Med"},{"key":"322_CR9","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019;88:102925.","journal-title":"Bioorg Chem"},{"key":"322_CR10","doi-asserted-by":"crossref","first-page":"175883591878647","DOI":"10.1177\/1758835918786475","volume":"10","author":"A Dubuc","year":"2018","unstructured":"Dubuc A, et al. Use of cold-atmospheric plasma in oncology: a concise systematic review. Ther Adv Med Oncol. 2018;10:1758835918786475.","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"322_CR11","doi-asserted-by":"crossref","first-page":"15977","DOI":"10.18632\/oncotarget.13304","volume":"8","author":"D Yan","year":"2017","unstructured":"Yan D, Sherman JH, Keidar M. Cold atmospheric plasma, a novel promising anti-cancer treatment modality. Oncotarget. 2017;8(9):15977\u201395.","journal-title":"Oncotarget"},{"issue":"6","key":"322_CR12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.tibtech.2017.06.013","volume":"36","author":"M Keidar","year":"2018","unstructured":"Keidar M, Yan D, Beilis II, Trink B, Sherman JH. Plasmas for Treating Cancer: Opportunities for Adaptive and Self-Adaptive Approaches. Trends Biotechnol. 2018;36(6):586\u201393.","journal-title":"Trends Biotechnol"},{"issue":"16","key":"322_CR13","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.3390\/app11167757","volume":"11","author":"D Yan","year":"2021","unstructured":"Yan D, Malyavko A, Wang Q, Lin L, Sherman JH, Keidar M. Cold Atmospheric Plasma Cancer Treatment, a Critical Review. Appl Sci. 2021;11(16):7757.","journal-title":"Appl Sci"},{"key":"322_CR14","doi-asserted-by":"crossref","unstructured":"Schlegel J, K\u00f6ritzer J, Boxhammer V. Plasma in cancer treatment. Clin Plasma Med. 2013;1(2):2\u20137.","DOI":"10.1016\/j.cpme.2013.08.001"},{"issue":"4","key":"322_CR15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3892\/ijmm.2014.1849","volume":"34","author":"R Guerrero-Preston","year":"2014","unstructured":"Guerrero-Preston R, et al. Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells. Int J Mol Med. 2014;34(4):941\u20136.","journal-title":"Int J Mol Med"},{"issue":"2","key":"322_CR16","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1038\/cddis.2014.33","volume":"5","author":"SU Kang","year":"2014","unstructured":"Kang SU, et al. Nonthermal plasma induces head and neck cancer cell death: The potential involvement of mitogen-activated protein kinase-dependent mitochondrial reactive oxygen species. Cell Death Dis. 2014;5(2):e1056.","journal-title":"Cell Death Dis"},{"issue":"11","key":"322_CR17","doi-asserted-by":"crossref","first-page":"e0141827","DOI":"10.1371\/journal.pone.0141827","volume":"10","author":"C Welz","year":"2015","unstructured":"Welz C, et al. Cold atmospheric plasma: A promising complementary therapy for squamous head and neck cancer. PLoS One. 2015;10(11):e0141827.","journal-title":"PLoS One"},{"key":"322_CR18","doi-asserted-by":"crossref","unstructured":"Welz C, et al. Effects of cold atmospheric plasma on mucosal tissue culture. J Phys D Appl Phys. 2013;46(4):045401.","DOI":"10.1088\/0022-3727\/46\/4\/045401"},{"issue":"31","key":"322_CR19","doi-asserted-by":"crossref","first-page":"34548","DOI":"10.1021\/acsami.0c06500","volume":"12","author":"D Yan","year":"2020","unstructured":"Yan D, et al. A Physically Triggered Cell Death via Transbarrier Cold Atmospheric Plasma Cancer Treatment. ACS Appl Mater Interfaces. 2020;12(31):34548\u201363.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"322_CR20","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.1038\/s41598-020-68585-z","volume":"10","author":"D Yan","year":"2020","unstructured":"Yan D, et al. The anti-glioblastoma effect of cold atmospheric plasma treatment: physical pathway vs chemical pathway. Sci Rep. 2020;10(1):11788.","journal-title":"Sci Rep"},{"issue":"3","key":"322_CR21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1520-6866(2000)20:3<119::AID-TCM3>3.0.CO;2-Z","volume":"20","author":"J Blasiak","year":"2000","unstructured":"Blasiak J, Kowalik J, Ma\u0142ecka-Panas E, Drzewoski J, Wojew\u00f3dzka M. DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs. Teratog Carcinog Mutagen. 2000;20(3):119\u201331.","journal-title":"Teratog Carcinog Mutagen"},{"issue":"11","key":"322_CR22","doi-asserted-by":"crossref","first-page":"115019","DOI":"10.1088\/1367-2630\/11\/11\/115019","volume":"11","author":"GE Morfill","year":"2009","unstructured":"Morfill GE, Shimizu T, Steffes B, Schmidt HU. Nosocomial infections\u2014a new approach towards preventive medicine using plasmas. New J Phys. 2009;11(11):115019.","journal-title":"New J Phys"},{"issue":"4","key":"322_CR23","doi-asserted-by":"crossref","first-page":"e34610","DOI":"10.1371\/journal.pone.0034610","volume":"7","author":"T Maisch","year":"2012","unstructured":"Maisch T, et al. Decolonisation of MRSA, S. aureus and E. coli by Cold-Atmospheric Plasma Using a Porcine Skin Model In Vitro. PLoS One. 2012;7(4):e34610.","journal-title":"PLoS One"},{"issue":"9","key":"322_CR24","doi-asserted-by":"crossref","first-page":"e22876","DOI":"10.1371\/journal.pone.0022876","volume":"6","author":"S-L Tran","year":"2011","unstructured":"Tran S-L, Puhar A, Ngo-Camus M, Ramarao N. Trypan blue dye enters viable cells incubated with the pore-forming toxin HlyII of Bacillus cereus. PLoS ONE. 2011;6(9):e22876\u2013e22876.","journal-title":"PLoS ONE"},{"key":"322_CR25","unstructured":"Merck, \u201cProtocol Guide: MTT Assay for Cell Viability and Proliferation | Sigma-Aldrich,\u201d Sigma-Aldrich, Inc., 2020. [Online]. Available: https:\/\/www.sigmaaldrich.com\/technical-documents\/protocols\/biology\/roche\/cell-proliferation-kit-i-mtt.html. [Accessed: 24 Jul 2020]."},{"issue":"1","key":"322_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nprot.2006.5","volume":"1","author":"PL Olive","year":"2006","unstructured":"Olive PL, Ban\u00e1th JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc. 2006;1(1):23\u20139.","journal-title":"Nat Protoc"},{"issue":"7","key":"322_CR27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1369\/0022155411410884","volume":"59","author":"EI Cort\u00e9s-Guti\u00e9rrez","year":"2011","unstructured":"Cort\u00e9s-Guti\u00e9rrez EI, D\u00e1vila-Rodr\u00edguez MI, Fern\u00e1ndez JL, L\u00f3pez-Fern\u00e1ndez C, Gos\u00e1lbez A, Gos\u00e1lvez J. New application of the comet assay: chromosome\u2013comet assay. J Histochem Cytochem. 2011;59(7):655\u201360.","journal-title":"J Histochem Cytochem"},{"key":"322_CR28","first-page":"1584","volume":"14","author":"M Mozaffarieh","year":"2008","unstructured":"Mozaffarieh M, et al. Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients. Mol Vis. 2008;14:1584\u20138.","journal-title":"Mol Vis"},{"issue":"4","key":"322_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-2001-13760","volume":"80","author":"NH Kleinsasser","year":"2001","unstructured":"Kleinsasser NH, Weissacher H, Wallner BC, Kastenbauer ER, Harr\u00e9us UA. Cytotoxicity and genotoxicity of fluorides in human mucosa and lymphocytes. Laryngorhinootologie. 2001;80(4):187\u201390.","journal-title":"Laryngorhinootologie"},{"issue":"1","key":"322_CR30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10565-007-9043-9","volume":"25","author":"TS Kumaravel","year":"2009","unstructured":"Kumaravel TS, Vilhar B, Faux SP, Jha AN. Comet Assay measurements: a perspective. Cell Biol Toxicol. 2009;25(1):53\u201364.","journal-title":"Cell Biol Toxicol"},{"issue":"3","key":"322_CR31","doi-asserted-by":"crossref","first-page":"033001","DOI":"10.1088\/0963-0252\/24\/3\/033001","volume":"24","author":"M Keidar","year":"2015","unstructured":"Keidar M. Plasma for cancer treatment. Plasma Sources Sci Technol. 2015;24(3):033001.","journal-title":"Plasma Sources Sci Technol"},{"issue":"9","key":"322_CR32","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/ijms18092004","volume":"18","author":"D G\u00fcmbel","year":"2017","unstructured":"G\u00fcmbel D, et al. Cold atmospheric plasma in the treatment of osteosarcoma. Int J Mol Sci. 2017;18(9):2004.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"322_CR33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/cancers13040615","volume":"13","author":"K Sklias","year":"2021","unstructured":"Sklias K, Santos Sousa J, Girard PM. Role of Short- and Long-Lived Reactive Species on the Selectivity and Anti-Cancer Action of Plasma Treatment In Vitro. Cancers. 2021;13(4):615.","journal-title":"Cancers"},{"issue":"1","key":"322_CR34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R","volume":"29","author":"SRS Rangan","year":"1972","unstructured":"Rangan SRS. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer. 1972;29(1):117\u201321.","journal-title":"Cancer"},{"issue":"9","key":"322_CR35","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0277-5379(88)90335-5","volume":"24","author":"J Gioanni","year":"1988","unstructured":"Gioanni J, et al. Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: Establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol. 1988;24(9):1445\u201355.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"322_CR36","unstructured":"ATCC, \u201cCAL 27 (ATCC CRL\u20102095).\u201d [Online]. Available:\u00a0https:\/\/www.lgcstandards-atcc.org\/products\/all\/CRL-2095.aspx?geo_country=de. Accessed 9 Feb 2020."},{"issue":"11","key":"322_CR37","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.oraloncology.2009.06.001","volume":"45","author":"L Jiang","year":"2009","unstructured":"Jiang L, et al. CAL 27 is an oral adenosquamous carcinoma cell line. Oral Oncol. 2009;45(11):e204\u20137.","journal-title":"Oral Oncol"},{"key":"322_CR38","unstructured":"Cellosaurus, \u201cCellosaurus OSC\u201019 (CVCL_3086).\u201d [Online]. Available:\u00a0https:\/\/web.expasy.org\/cellosaurus\/CVCL_3086. Accessed 27 Mar 2020.\u00a0"},{"key":"322_CR39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/srep00636","volume":"2","author":"O Volotskova","year":"2012","unstructured":"Volotskova O, Hawley TS, Stepp MA, Keidar M. Targeting the cancer cell cycle by cold atmospheric plasma. Sci Rep. 2012;2:636.","journal-title":"Sci Rep"},{"issue":"5","key":"322_CR40","doi-asserted-by":"crossref","first-page":"e64498","DOI":"10.1371\/journal.pone.0064498","volume":"8","author":"J K\u00f6ritzer","year":"2013","unstructured":"K\u00f6ritzer J, et al. Restoration of Sensitivity in Chemo \u2014 Resistant Glioma Cells by Cold Atmospheric Plasma. PLoS ONE. 2013;8(5):e64498.","journal-title":"PLoS ONE"},{"issue":"17","key":"322_CR41","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.3390\/cancers13174485","volume":"13","author":"V Soni","year":"2021","unstructured":"Soni V, et al. In Vitro and In Vivo Enhancement of Temozolomide Effect in Human Glioblastoma by Non-Invasive Application of Cold Atmospheric Plasma. Cancers. 2021;13(17):4485.","journal-title":"Cancers"},{"key":"322_CR42","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.biocel.2020.105732","volume":"122","author":"D Xue","year":"2020","unstructured":"Xue D, Pan ST, Huang G, Qiu J. ROS Enhances the Cytotoxicity of Cisplatin by Inducing Apoptosis and Autophagy in Tongue Squamous Cell Carcinoma Cells. Int J Biochem Cell Biol. 2020;122:105732.","journal-title":"Int J Biochem Cell Biol"},{"key":"322_CR43","doi-asserted-by":"crossref","first-page":"640392","DOI":"10.3389\/fonc.2021.640392","volume":"11","author":"Y Kanno","year":"2021","unstructured":"Kanno Y, Chen C-Y, Lee H-L, Chiou J-F, Chen Y-J. Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. Front Oncol. 2021;11:640392.","journal-title":"Front Oncol"},{"issue":"3","key":"322_CR44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/01635581.2013.749290","volume":"66","author":"S Ibrahim","year":"2014","unstructured":"Ibrahim S, Gao D, Sinko PJ. Selective cytotoxicity and combined effects of camptothecin or paclitaxel with sodium-R-alpha lipoate on A549 human non-small cell lung cancer cells. Nutr Cancer. 2014;66(3):492\u20139.","journal-title":"Nutr Cancer"},{"issue":"3","key":"322_CR45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00003495-199957030-00003","volume":"57","author":"M Links","year":"1999","unstructured":"Links M, Lewis C. Chemoprotectants. Drugs. 1999;57(3):293\u2013308.","journal-title":"Drugs"},{"key":"322_CR46","doi-asserted-by":"crossref","first-page":"175883591878647","DOI":"10.1177\/1758835918786475","volume":"10","author":"A Dubuc","year":"2018","unstructured":"Dubuc A, et al. Use of cold-atmospheric plasma in oncology: a concise systematicreview. Ther Adv Med Oncol. 2018;10:1758835918786475.","journal-title":"Ther Adv Med Oncol"},{"issue":"20","key":"322_CR47","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.3390\/ijms21207646","volume":"21","author":"CM Lee","year":"2020","unstructured":"Lee CM, Jeong YI, Kook MS, Kim BH. Combinatorial Effect of Cold Atmosphere Plasma (CAP) and the Anticancer Drug Cisplatin on Oral Squamous Cell Cancer Therapy. Int J Mol Sci. 2020;21(20):7646.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"322_CR48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/archotol.132.3.317","volume":"132","author":"HT Yip","year":"2006","unstructured":"Yip HT, et al. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53. Arch Otolaryngol Head Neck Surg. 2006;132(3):317\u201326.","journal-title":"Arch Otolaryngol Head Neck Surg"}],"updated-by":[{"DOI":"10.1186\/s13005-023-00386-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000}}],"container-title":["Head &amp; Face Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13005-022-00322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13005-022-00322-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13005-022-00322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T04:04:49Z","timestamp":1692763489000},"score":1,"resource":{"primary":{"URL":"https:\/\/head-face-med.biomedcentral.com\/articles\/10.1186\/s13005-022-00322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1186\/s13005-022-00322-5","relation":{},"ISSN":["1746-160X"],"issn-type":[{"value":"1746-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13005-023-00386-x","URL":"https:\/\/doi.org\/10.1186\/s13005-023-00386-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}